1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

Herpes Simplex Virus Reactivation Induced *Ex Vivo* Involves a DLK-Dependent but Histone
Demethylase-Independent Wave of Lytic Gene Expression

Abigail L. Whitford¹, Corinne A. Clinton¹, E.B. Lane Kennedy¹, Sara A. Dochnal¹, Jon B.
Suzich¹ and Anna R. Cliffe^{1,*}

1. Department of Microbiology, Immunology and Cancer Biology, University of Virginia,
Charlottesville, VA, 22908.

* Correspondence to Anna R. Cliffe, cliffe@virginia.edu

Abstract

Herpes Simplex virus-1 (HSV-1) maintains a lifelong latent infection in neurons and periodically reactivates, resulting in the production of infectious virus. The exact cellular pathways that induce reactivation are not understood. In primary neuronal models of HSV latency, the cellular protein Dual Leucine Zipper kinase (DLK) has been found to initiate a wave of viral gene expression known as Phase I. Phase I occurs independently of both viral DNA replication and the activities of histone demethylase enzymes required to remove repressive heterochromatin modifications associated with the viral genome. Here we investigated whether Phase-I like gene expression occurs in ganglia reactivated from infected mice. Using the combined trigger of explant-induced axotomy and inhibition of PI3K signaling, we found that DLK was required for the initial induction of lytic gene expression. *Ex vivo* reactivation involved a wave of viral late gene expression that occurred independently of viral genome synthesis and histone demethylase activity. These data confirm the essential role of DLK in inducing HSV-1 gene expression from the heterochromatin associated genome and further demonstrate that HSV-1 gene expression during reactivation occurs via mechanisms that are distinct from lytic replication.

Introduction

The ubiquitous human pathogen Herpes Simples Virus persists for life in the form of a latent infection in neurons. In response to a variety of different stimuli, the virus can reactivate from the latent state, resulting in the release of infectious virus and subsequent replication in the surrounding tissue. Clinically, reactivation of the virus can manifest as a variety of disease states including lesions at the body surface, keratitis, and encephalitis. In addition, there is growing evidence of a link between HSV infection and the development of late onset Alzheimer's disease, particularly in individuals with the ApoE4 variant (1-9). There are potentially different stimuli that can induce HSV to reactivate from latency. These stimuli may converge on single cellular pathways or operate via distinct mechanisms to induce reactivation (10). Identifying the cellular pathways important in reactivation is required to understand how viral gene expression initiates from the latent genome and to ultimately develop therapeutics to prevent reactivation occurring.

During a latent infection of neurons, the HSV genome is assembled into repressive heterochromatin. This has been characterized by the enrichment of post-translational modifications on histone H3; namely di- and tri-methyl lysine 9 (H3K9me2/3) and tri-methyl lysine 27 (H3K27me3) on lytic promoters (11-17). By assembling into heterochromatin, viral lytic transcripts are maintained in a silent state. In addition, both host and viral miRNAs target lytic mRNAs (18-22). Therefore, the action of transcriptional and translational silencing results in limited synthesis of viral lytic proteins. This lack of lytic proteins suggests that HSV is reliant upon host signaling to initiate gene expression and reactivation. To understand the mechanism of HSV reactivation, it is important to determine how activation of host cell pathways ultimately converge on the repressed viral genome to induce lytic gene expression.

There is evidence that the initial induction of HSV-1 lytic gene expression following reactivation occurs in a manner that is distinct from the mechanisms of viral gene expression during lytic replication. HSV lytic genes can be divided into groups characterized by their requirements for viral protein synthesis and viral DNA replication during lytic replication (23). Immediate early (IE) genes are expressed independently viral protein synthesis during lytic infection and instead require the viral tegument protein VP16 for maximal expression. Early (E) genes are expressed following the production of IE proteins. Certain IE proteins (including ICP4, ICP0 and ICP27) stimulate viral E protein synthesis. Late (L) genes require viral DNA synthesis and are subdivided into genes that are expressed at low levels even prior to DNA replication but increased with genome synthesis (leaky L) and those that are fully dependent on viral DNA replication (true L). The dependence on DNA replication for L gene expression is not fully understood but likely involves a shift in genome accessibility and increased binding of host transcriptional machinery (RNA Pol II, TBP, and TAF1) (24). In contrast to this regulated cascade, in models of HSV reactivation, an initial burst of lytic gene expression, named Phase I of reactivation, has been observed where inhibition of protein synthesis prior to the accumulation of IE transcripts does not prevent E gene expression (25). In addition, L gene expression is unaffected by inhibition of viral DNA replication (25). Together, these data indicate that initial expression of lytic transcripts during the early stages of reactivation does not resemble the early stages of *de novo* infection in non-neuronal cells.

Phase I of HSV reactivation has largely been identified in primary neuronal models of HSV latency (26). In these experimental models, a variety of stimuli have been found to induce HSV to reactivate from a latent infection, including loss of neurotrophic factor support (25, 27-29), increased neuronal excitation (30), modulation of DNA damage/repair (31) and exposure to corticosteroids (27). Precisely how activation of these pathways permits

expression of the viral gene transcripts for reactivation to occur is not fully understood. Previously, we have identified a role for the cell stress protein, dual leucine zipper kinase (DLK), in inducing Phase I of HSV reactivation (27). DLK is activated by the loss of neurotrophic factor support, which can be mimicked by inhibition of Phosphoinositide 3 (PI3)-kinase activity (27), and during heightened neuronal excitation and interleukin-1 (IL-1) treatment (30). DLK is a master regulator of axonal responses to stress and can mediate a variety of responses including Wallerian degeneration, axon regeneration, apoptosis, and axon pruning (32). Upon activation, DLK is known to re-direct the cell stress protein, c-Jun N-terminal kinase (JNK), from its physiological role in neurons, maintaining synaptic arborization, to its cell stress function (33). Accordingly, we and others have identified a role for JNK in reactivation of HSV from latency (27, 30, 31). JNK is also important in reactivation of the related Alpha herpesvirus, Varicella-Zoster virus, from a latent infection (34) highlighting its potential central role in reactivation of human Alpha herpesviruses.

A role for DLK and JNK in HSV reactivation has been mostly widely studied on primary neuronal models of latency in murine sympathetic neurons (27, 30). In these neurons, latency is established in the presence of the HSV DNA replication inhibitor, acyclovir. After the removal of acyclovir, reactivation can be induced by PI3-kinase inhibition or forskolin (25, 27, 30, 35, 36). In these systems, full reactivation occurs around 48h post-stimulus, which requires the activities of histone demethylase enzymes, indicating that reactivation requires removal of repressive heterochromatin (27, 30). However, the DLK-dependent Phase I peaks around 18h post-stimuli and (27, 30, 37), importantly, Phase I occurs independently of lysine 9 and lysine 27 histone demethylase activity (27, 30). Instead, JNK activation induces histone phosphorylation on H3Serine10 (H3S10) on histones that maintain the H3K9me3 modification (27); this is known as a histone methyl/phospho switch and presumably permits

transcription by overriding the repressive H3K9me3 modification. However, although demonstrated *in vitro*, the possibility of a DLK/JNK-dependent wave of gene expression, characteristic of Phase I, has not been explored following *in vivo* infections.

A robust mode of HSV reactivation from infected mice is explanation of the sensory trigeminal ganglia (TG). The action of severing the axon (axotomy), is thought to be the trigger that induces HSV to reactivate. In this model, whether a Phase I-like wave of gene expression occurs has not been fully explored. Data from a previous study suggests that a H3 lysine 9 demethylase functions to promote lytic gene expression at an early time-point (6 hours post-explant) (38). This indicates that wave of gene expression that is independent of histone demethylase activity occurs at an earlier time-point, or that explant induced reactivation does not involve a Phase-I like wave of viral gene expression. There are multiple differences between the *in vivo* experiments and *in vitro* latency models, including the presence of host immune system *in vivo*. In addition, explant-induced reactivation has been investigated mostly in sensory neurons whereas models for *in vitro* infection often use sympathetic neurons; both neuronal types are targets of HSV latent infection in humans (2, 39-41). *In vitro* models also use acyclovir to promote the establishment of latency. Finally, potential differences resulting from viral strains used cannot be ruled out. In experiments investigating the role for histone demethylases *ex vivo*, HSV strain F was used (16, 38), whereas the *in vitro* models have been performed with the KOS and Patton strains (25, 27).

To determine whether previous observations of a DLK/JNK triggered Phase I reactivation *in vitro* were recapitulated *ex vivo*, we dissected trigeminal ganglia from latently infected mice and determined whether we observed lytic gene expression in response to PI3-kinase inhibition. We found that after only five hours post excision, in treated ganglia, there

135 was robust expression of IE, E, and L viral genes and this gene expression was independent
 136 of viral DNA replication. Supporting previous findings, we also found that this initial burst of
 137 lytic gene expression was not dependent upon LSD1 (H3K9-demethylase) nor JMJD3 and
 138 UTX (H3K27-demethylases). Therefore, Phase I of reactivation was observed *ex vivo* and
 139 was not reliant upon the removal of repressive heterochromatic marks. We found that this
 140 Phase 1 was dependent upon DLK, thus indicating that neuronal stress pathways can trigger
 141 bi-phasic reactivation of HSV-1 in ganglia *ex vivo*.

142

143

144

Materials Methods

Cells and Viruses

HSV-1 stocks of KOS were grown and titrated on Vero cells obtained from the American Type Culture Collection (Manassas, VA) as described previously (11). Cells were maintained in Dulbecco's Modified Eagle's Medium (Gibco) supplemented with 10% FetalPlex (Gemini Bio-Products) and 2 mM L-Glutamine. KOS was kindly provided by Dr. David Knipe, Harvard Medical School.

Reagents

Compounds used in the study are as follows: Acycloguanosine (acyclovir; ACV), GSK-J4 and GNE-3511 (Millipore Sigma) SP600125 (Thermo Fisher Scientific), OG-L002 (Tocris); Nerve Growth Factor 2.5S (Alomone Labs).

Mouse Infections

Six-week-old male and female CD-1 mice (Charles River Laboratories) were anesthetized by intraperitoneal injection of ketamine hydrochloride (80mg/kg) and xylazine hydrochloride (10mg/kg) and inoculated with 1.5×10^6 PFU/eye of virus (in a 5 μ l volume) onto scarified corneas, as described previously (11). Mice were housed in accordance with institutional and National Institutes of Health guidelines on the care and use of animals in research, and all procedures were approved by the Institutional Animal Care and Use Committee of the University of Virginia. Criteria used for clinical scoring based on the formation of lesions, neurological and eye symptoms is shown in table 1 and based on a previously establishing scoring scale (42). Mice were randomly assigned to groups and all experiments included biological repetitions from independent litters.

170

171 **Table 1. Clinical scoring scale for HSV infected mice.**

Score	Description of score by type		
	Lesion	Eye	Neurological
0	Lesion free	Symptom free	Symptom free
1	Small area of broken skin <0.5cm	Pus around edges	Hunched posture, normal movement
2	Area of broken skin 0.5-1 cm	Pus and squint	Hunched posture, slow movement
3	Bleeding, scabbing or pustules	Closed	Hunched posture, labored breathing and/or hind leg paralysis
4	Broken skin >cm with multiple pustules or scabbing	Scab formation	Hunched, ruffled fur, little to no movement
5	Sever scabbing or bleeding with pustules	Sever scabbing	Moribund or dead

172

173

174 Explant Induced Reactivation

175 Trigeminal ganglia (TG) and superior cervical ganglia (SCG) were removed at least 28 days
 176 post-infection. The ganglia were maintained intact and immediately placed in reactivation
 177 media containing DMEM/F12 (Gibco) supplemented with 10% Fetal Bovine Serum and
 178 Mouse NGF 2.5S (50 ng/mL). Compounds were added at the following concentrations;
 179 LY294002 40μM, GNE-3511 8μM, ACV 100μM, GSK-J4 10μM, OG-L002 50μM. For
 180 treatments with GNE-5311, ACV, GSK-J4 and OG-L002, ganglia were treated with the
 181 compounds 3-60 minutes prior to the addition of LY294002. Ganglia were placed on a
 182 shaking platform at 50rpm at 37°C.

183

184 Quantification of Viral Transcripts and Genome Copy Number

185 At the required time point, the reactivation media was removed and ganglia snap-frozen in
 186 liquid nitrogen. Lysis was carried out by addition of the excised ganglia to BeadBug
 187 homogenization microtubules then homogenized for 60 seconds using the BeadBug
 188 microtube homogenizer. DNA and RNA were isolated from the homogenized mixture using

the *Quick* DNA/RNA miniprep kit. Following RNA isolation TURBO DNA-free Kit (Invitrogen) was used to remove any contaminant DNA. mRNA was reverse transcribed into cDNA using MaximaRT (ThermoFisher) using random hexamers for first strand synthesis. Equal amounts of mRNA were used for each reverse transcriptase experiment (20-30 ng/reaction). Power SYBR Green PCR Master Mix was used for qPCR (Applied Biosystems). Standard Curves were used to calculate the relative mRNA or DNA copy number per genome and were standardized to cellular GAPDH or 18s. All RNA samples were run in triplicate and all DNA samples were run in duplicate on an Applied Biosystems™ QuantStudio™ 6 Flex Real-Time PCR System. The primers that were used are described in Table 2.

Table 2. Oligonucleotides used in this study

Primer	Sequence 5'-3'
GAPDH F	CAT GGC CTT CCG TGT TCC TA
GAPDH R	GCG GCA CGT CAG ATC CA
18s F	CAC GGA CAG GAT TGA CAG ATT
18s R	GCC AGA GTC TCG TTC GTT ATC
ICP27 F	GCA TCC TTC GTG TTT GTC ATT CTG
ICP27 R	GCA TCT TCT CTC CGA CCC CG
ICP8 F	GGA GGT GCA CCG CAT ACC
ICP8 R	GGC TAA AAT CCG GCA TGA AC
gC F	GAG TTT GTC TGG TTC GAG GAC
gC R	ACG GTA GAG ACT GTG GTG AA

Results

Explant combined with PI3-kinase inhibition triggers robust HSV-1 lytic gene expression

We first set out to determine whether a wave of lytic gene expression occurs following reactivation of explanted ganglia, similar to what has been observed in primary neuronal cultures. Female mice were infected via the ocular route and reactivation studies were carried out at least 28 days post-infection. Previously, studies from our lab and others have shown that addition of a reactivation stimulus to sympathetic neurons infected *in vitro* yields induction of lytic viral gene expression around 15-20 hours post-stimulus (25, 27). In addition, a previous study examining explant induced reactivation combined with deprivation of nerve growth factor (NGF) also resulted in lytic gene induction around 12-15 hours post-explant (43). Therefore, we initially examined the effect of PI3-K inhibition (using LY294002; 40 μ M) at 20 hours post-reactivation to determine whether loss of the PI3K/AKT branch of the NGF-signaling pathway also promotes reactivation *ex vivo*. Acyclovir (ACV; 100 μ M) was also introduced alongside LY294002 because late gene expression during the initial activation of viral gene expression in *in vitro* models has been reported to proceed independently of DNA replication (25).

In ganglia that were explanted and maintained in NGF to provide continued neurotrophin support, very little induction of lytic gene expression was observed at 20h post-explant, especially for representative IE and E transcripts. A slight increase in gC mRNA was observed, although this increase was not statistically significant ($P=0.1255$, Mann Whitney U Test). However, the addition of the PI3-kinase inhibitor (LY294002) increased viral gene expression by 100-1000-fold. RT-qPCRs were carried out using primers against IE (ICP27,

FIG.1. Explant combined with PI3-kinase inhibition triggers robust HSV-1 lytic gene expression

Mice were infected via corneal scarification and at least 28 days post infection trigeminal ganglia were excised. Ganglia were either snap frozen at 0 hours, or reactivated for 20 hours in media alone, with LY294002 (40 μ M) or LY294002 with acyclovir (ACV; 100 μ M). (A) Viral genome copy number was quantified by qPCR. (B) Viral gene expression was quantified by RT-qPCR for immediate early (*ICP27*), (C) early (*ICP8*) and (D) and late (*gC*) genes. Transcript copy number was normalized to cellular control (GAPDH). n=6 biological replicates. Mann-Whitney U (A-D). *p<0.05, **p<0.01. Individual biological replicates along with the means and SEMs are represented.

Fig.1 B), E (ICP8, Fig. 1C) and L (gC, Fig. 1D) genes. All three genes were significantly induced at 20h post excision. The addition of ACV to inhibit viral DNA replication did not inhibit the induction of IE or E gene expression, as expected. However, expression of the gC mRNA was significantly reduced in the presence of ACV, indicating that its maximal expression was dependent on viral genome synthesis. However, gC mRNA levels with ACV were still significantly increased compared to the latent samples. At 20h post-reactivation, an increase in viral genomes was also observed (Fig. 1A). Together, these data show that at 20h post-reactivation viral gene expression does not resemble the Phase I observed in primary neuronal cultures, as genome synthesis has occurred, and full late gene expression is dependent on viral DNA replication. However, this did not rule out the possibility of a Phase I-like wave of gene expression occurring prior to 20h, especially as gC mRNA was still induced compared to the 0h (latent) samples, indicating that there may still be some gC expression occurred even from non-replicated viral genomes.

PI3K inhibition/explant induces rapid late gene expression in the absence of detectable genome synthesis in trigeminal ganglia

To determine whether viral lytic gene expression occurred prior to 20h post-stimulus in explanted ganglia with features characteristic of Phase I gene expression, we decided to undertake both male and female mice and determine changes in lytic gene expression following PI3-kinase inhibition of explanted ganglia. Because we infected both male and female mice, we assessed if sex impacted clinical manifestations of infection, mice were monitored throughout the period of infection. Both male and female mice had minimal mortality with only 92 and 88 percent mortality respectively. The mortality rates between sexes were not found to be significant by Kaplan-Meier survival analysis (Fig. 2A). To further

FIG. 2: Sex dependent phenotypes during HSV-1 *in vivo* infection.

Mice were infected via corneal scarification and monitored post infection. (A) Survival over time was observed and the significance of the percentage survival between female and male mice were analyzed using Kaplan-Meier survival analysis. (B) Clinicals scores were calculated by scoring lesion, neurological, and eye phenotypes as outlined in table 1. (C) Percent weight compared to pre-infection weights. Student T test (B-C). *p<0.05. The mean and SEM are represented. N= 13 females, 8 males.

analyze clinical symptoms, mice were evaluated by scoring lesions, neurological symptoms and eye health based on a previously described scoring metric (42). Infection of female mouse resulted in more severe clinical manifestations at days 7 and 9 post-infection (Fig. 2B). Despite these differences, there was no significant differences in the percentage of weight loss following infection between male and female mice (Fig. 2C). Based on these criteria, we concluded there were only minor sex-dependent differences upon HSV infection.

After at least 28 days post-infection, ganglia were explanted and incubated in the presence of the PI3-kinase inhibitor, LY294002, with and without ACV. Values from both male and female mice were combined (Fig. 3A-D). Quantification of viral DNA loads showed that the copy number of viral genomes stayed constant up to 15 hours post-stimuli and were not affected by the presence of ACV, indicating that detectable viral genome synthesis did not occur in this time period. In contrast, a robust induction of viral lytic gene expression occurred by 5h post-stimuli, as induced by an increase in IE (ICP27), E (ICP8) and late (gC) mRNA copy number. For all gene classes examined, the increase in copy number was 100-fold for IE mRNA (Fig. 3B), 20-fold for E mRNA (Fig. 3C), and 10-fold for L mRNA (Fig. 3D) 5 hours post explant. The robust increase in late gene expression in the absence of detectable viral genome synthesis suggested that late gene expression could occur even prior to DNA replication. To further support this conclusion, late gene induction occurred to equivalent levels even in the presence of ACV. The inclusion of ACV did prevent genome synthesis at 20h post-stimuli (Fig. 1A), indicating that the ACV was capable of acting on the explanted ganglia. Therefore, these data indicate that the induction of lytic gene expression following PI3-kinase inhibition in explanted sensory neurons resembles at least one feature of Phase I gene expression as viral late gene expression occurred independently of viral DNA replication.

FIG. 3: PI3K inhibition of explanted trigeminal ganglia induces rapid lytic gene expression in the absence of detectible genome synthesis

Latently infected TGs from male and female mice were reactivated for 5, 10 or 15 hours with LY294002 in the presence and absence of acyclovir. (A) Viral genome copy number was quantified by PCR. Viral gene expression also was quantified by RT-qPCR for (B) immediate early (*ICP27*), (C) early (*ICP8*), and (D) late (*gC*) genes. The average genome copy number (E) and *ICP27* mRNA transcripts (F) for male and female mice were calculated. Transcript copy number was normalized to cellular control (18s). Limit of detection indicated by black dashed line. $N \geq 19$ biological replicates (A-D). Mann-Whitney U (A-F). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. **** $p < 0.0001$. The means and SEMs are represented.

To confirm that reactivation had no sex-dependent effects we performed quantification of viral lytic gene expression in both male and female mice. We found no difference in viral genome copy number (Fig. 2E) or ICP27 lytic gene expression (Fig. 2F) at any time point. We therefore concluded that the observed phenotypes in lytic gene expression were sex-independent.

DLK activity is required for reactivation *ex vivo*

Previously, we have found that the neuronal cell stress protein dual leucine zipper kinase (DLK) is required for HSV reactivation and acts to induce Phase I lytic gene expression. To determine whether DLK was also required for induction of lytic gene expression in sensory neurons infected *in vivo* and induced reactivation *ex vivo* in a PI3K-inhibition dependent manner, the DLK inhibitor GNE-3551 was added to the explanted ganglia and viral RNA was extracted at 5h post-reactivation. Inclusion of the DLK-inhibitor resulted in ICP27, ICP8, and gC mRNA levels that were equivalent to the un-reactivated samples and significantly decreased compared to the reactivated ganglia that were not treated with the DLK-inhibitor (Fig. 4). These data indicate that DLK is required for reactivation from sensory neurons induced by the combined trigger of explant and PI3-kinase inhibition.

Fig. 4: DLK activity is required for the induction of lytic gene expression following explant/PI3-kinase inhibition of latently infected TG.

Latently infected TG were explanted and incubated with LY294002 and the DLK inhibitor GNE-3511 (8 μ M) for 5 hours post excision. Viral gene expression was quantified by RT-qPCR for immediate early (*ICP27*) (**A**), early (*ICP8*) (**B**), and late (*gC*) (**C**) genes. Transcript copy number was normalized to cellular control (18s). Limit of detection indicated by black dashed line. n=12 biological replicates. Mann-Whitney U test. *p<0.05, **p<0.01. Individual biological replicates along with the means and SEMs are represented.

303

304

Lytic gene induction upon axotomy along with PI3-kinase inhibition is independent of histone H3 histone lysine 9 and lysine 27 demethylase inhibitors

HSV promoters are known to be enriched with histone H3 di- and trimethyl at lysine 9 (H3K9me2/3) and histone H3 trimethyl at lysine 27 (H3K27me3) during latency. The removal of restrictive histone modifications, specifically the aforementioned methylation marks, was previously shown to be essential for full reactivation of HSV *in vitro*, yet was not required for initial lytic gene expression during Phase I of reactivation (27, 30). To determine if initial lytic gene expression was independent of histone demethylation *ex vivo*, we used OG-L002 (60 μ M), a drug that inhibits the histone lysine 9 demethylase LSD1, and GSK-J4 (20 μ M), a molecule that inhibits the histone lysine 27 demethylases UTX and JMJD3. HSV reactivation has been demonstrated to be inhibited by both of these inhibitors (27, 30, 44, 45). Five hours post excision, during Phase I of reactivation, the addition of OG-L002 and GSK-J4 had no effect on the induction of ICP27, ICP8, or gC mRNA (Fig. 5). These results emphasize the observation that histone demethylase activity is not required for the initial induction of lytic gene expression induced by axotomy and PI3-kinase inhibition *ex vivo*.

Together, our results demonstrate that features of Phase I gene expression, namely late gene expression in the absence of viral DNA replication and lytic gene expression in the presence of histone demethylase inhibitors, can occur from ganglia isolated from infected mice. In addition, *ex vivo* reactivation was dependent on DLK activity.

Fig. 5: Lytic gene induction following axotomy/PI3-kinase inhibition is unaffected by histone demethylase inhibitors.

Latently infected TG were explanted and incubated with LY294002 along with the LSD1 inhibitor OG-L1002 (50 μ M) or GSK-J4 (20 μ M). Viral gene expression was quantified by RT-qPCR for immediate early (*ICP27*) (A), early (*ICP8*) (B), and late (*gC*) (C) genes. Transcript copy number was normalized to cellular control (18s) Mann-Whitney U (A-C), ** $p < 0.01$, *** $p < 0.001$. Individual biological replicates along with the means and SEMs are represented.

329

330 Discussion

331 *In vitro* models of HSV latency are incredibly powerful for the study of molecular
332 mechanisms HSV latency and reactivation as well as the contribution of host factors and viral
333 factors during specific stages of infection. *In vitro* models can be used to investigate how the
334 host immune response can modulate latent infection and reactivation. Using these models,
335 unique aspects regarding entry into lytic gene expression during reactivation have been
336 uncovered, including the dependence on DLK/JNK for reactivation, the ability of late gene
337 expression to occur in the absence of DNA replication, and transcription despite the presence
338 of histone demethylase inhibitors. Therefore, it was highly important to validate these patterns
339 of gene expression from ganglia infected *in vivo*. Here we have confirmed that the features of
340 gene expression observed during Phase I reactivation *in vitro* also occur following
341 reactivation *ex vivo* when PI3k-inhibition and axotomy is used as a trigger.

342

343 There are certain caveats to our study, especially relating to the ability of inhibitors to
344 act on intact ganglia. However, we show that the DLK inhibitor, PI3-kinase inhibitor and
345 acyclovir can all act on intact ganglia. Therefore, we think it unlikely that the histone
346 demethylase inhibitors used were unable to penetrate the tissue and have an effect on viral
347 lytic gene induction. The concentrations of histone demethylase inhibitors were higher than
348 what we have previously observed to inhibit full HSV reactivation in primary neuronal models
349 (27, 30). We have shown that OG-L002 can inhibit forskolin mediated reactivation at 30 μ M,
350 here we used 60 μ M. Similarly, we have shown that GSK-J4 can inhibit both forskolin and
351 LY294002 induced reactivation at 3 μ M; here we used it at 20 μ M. Therefore, we think it
352 unlikely that the concentrations used were too low to inhibit the histone demethylases. We did

try higher concentrations, but these resulted in loss of viral genomes at 5h, indicating potential neuronal toxicity at these higher concentrations.

Our study did result in the discovery of a unique phenotype of Phase I of reactivation when observed *ex vivo*. Unlike our previous *in vitro* studies, we found that Phase I of reactivation that occurred *ex vivo* had enhanced kinetics of lytic gene induction upon axotomy and PI3-kinase stimulation. Previous *in vitro* experiments involved sympathetic neurons, whereas here we investigated reactivation in sensory neurons. However, in a novel model of latency and reactivation using a virus defective in cell spread, our lab has determined that reactivation from sensory and sympathetic intact neurons *in vitro* occurred with similar kinetics (Dochal et al, manuscript in preparation). Therefore, we posit that the most likely explanation of the difference in reactivation kinetics is the combined trigger of axotomy and PI3-kinase inhibition. It has previously been demonstrated that when nerve growth factor deprivation is paired with axotomy, treated neurons undergo cell death more quickly than untreated neurons. (46). In addition, both PI3-kinase inhibition and axotomy result in activation of DLK (32, 47). However, there are some differences in how DLK is activated and the resulting downstream response in response to the two stimuli. Following axotomy, DLK is rapidly activated at the proximal segment of the severed axon in response to loss of cytoplasmic integrity and a calcium influx results from cytoplasmic membrane rupture to ultimately result in transcription of genes involved in axon regeneration (48). The exact mechanisms of DLK activation upon loss of NGF signaling that mediates neuronal cell death or axon pruning is not fully understood. It is known that in response to NGF deprivation, DLK protein levels are stabilized, DLK is phosphorylated (49), and this phosphorylation results in the downstream activation of JNK, c-Jun, and other transcription factors. The activation of

these transcription factors promotes the expression of pro-apoptotic genes (50), although in mature neurons there are multiple brakes downstream that prevent apoptosis (51). It is therefore conceivable that these two independent pathways to DLK activation may converge follow the dual trigger of axotomy/PI3-kinase inhibition to result in more rapid and robust DLK activation and HSV reactivation.

Consistent with cellular pathways converging the enhance DLK activity, we observed a robust induction of lytic gene expression at 5h post reactivation. For the IE gene ICP27 this was an approximate 100-fold induction, compared to the 5-20-fold increase often observed in an *in vitro* mouse model with PI3-kinase inhibition (27). The use of an *ex vivo* model system will therefore be incredibly powerful for studying the mechanisms of gene expression that occur during Phase I. We have previously observed a histone methyl/phospho switch on lytic promoters during Phase I reactivation (27), which permits lytic gene expression independently of recruitment of histone demethylase enzymes. There is evidence that the methyl/phospho switch permits gene expression because repressive histone readers (for example HP1) are no longer capable of interacting with the methylated residue on histone H3K9 because phosphorylation at Serine 10 occludes binding (52, 53). Because of the robust lytic gene induction *ex vivo*, and because we have now shown that the gene expression both *in vitro* and *ex vivo* is DLK-dependent and histone demethylase independent, the complementary models can now be used answer key questions on the mechanism of viral lytic gene induction during Phase I reactivation.

403 Acknowledgements

404 We thank David Knipe (Harvard Medical School) for the KOS virus. This work was supported
405 by R01NS105630 (ARC), The Owens Family Foundation (ARC), NIH/NIAID T32AI007046
406 (ALW, JBS), NIH/NEI F30EY030397 JBS) and NIH/NIGMS T32GM008136 (SAD).

407 **References**

- 408 1. Jamieson GA, Maitland NJ, Wilcock GK, Craske J, Itzhaki RF. 1991. Latent herpes simplex virus
409 type 1 in normal and Alzheimer's disease brains. *J Med Virol* 33:224-7.
- 410 2. Baringer JR, Pisani P. 1994. Herpes simplex virus genomes in human nervous system tissue
411 analyzed by polymerase chain reaction. *Ann Neurol* 36:823-9.
- 412 3. Itzhaki RF, Lin WR, Shang D, Wilcock GK, Faragher B, Jamieson GA. 1997. Herpes simplex virus
413 type 1 in brain and risk of Alzheimer's disease. *Lancet* 349:241-4.
- 414 4. Mori I, Kimura Y, Naiki H, Matsubara R, Takeuchi T, Yokochi T, Nishiyama Y. 2004. Reactivation
415 of HSV-1 in the brain of patients with familial Alzheimer's disease. *J Med Virol* 73:605-11.
- 416 5. Piacentini R, De Chiara G, Li Puma DD, Ripoli C, Marcocci ME, Garaci E, Palamara AT, Grassi C.
417 2014. HSV-1 and Alzheimer's disease: more than a hypothesis. *Front Pharmacol* 5:97.
- 418 6. Itzhaki RF. 2018. Corroboration of a Major Role for Herpes Simplex Virus Type 1 in Alzheimer's
419 Disease. *Front Aging Neurosci* 10:324.
- 420 7. De Chiara G, Piacentini R, Fabiani M, Mastrodonato A, Marcocci ME, Limongi D, Napoletani G,
421 Protto V, Coluccio P, Celestino I, Li Puma DD, Grassi C, Palamara AT. 2019. Recurrent herpes
422 simplex virus-1 infection induces hallmarks of neurodegeneration and cognitive deficits in
423 mice. *PLoS Pathog* 15:e1007617.
- 424 8. Tzeng NS, Chung CH, Lin FH, Chiang CP, Yeh CB, Huang SY, Lu RB, Chang HA, Kao YC, Yeh HW,
425 Chiang WS, Chou YC, Tsao CH, Wu YF, Chien WC. 2018. Anti-herpetic Medications and
426 Reduced Risk of Dementia in Patients with Herpes Simplex Virus Infections-a Nationwide,
427 Population-Based Cohort Study in Taiwan. *Neurotherapeutics* 15:417-429.
- 428 9. Readhead B, Haure-Mirande JV, Funk CC, Richards MA, Shannon P, Haroutunian V, Sano M,
429 Liang WS, Beckmann ND, Price ND, Reiman EM, Schadt EE, Ehrlich ME, Gandy S, Dudley JT.
430 2018. Multiscale Analysis of Independent Alzheimer's Cohorts Finds Disruption of Molecular,
431 Genetic, and Clinical Networks by Human Herpesvirus. *Neuron* 99:64-82 e7.
- 432 10. Suzich JB, Cliffe AR. 2018. Strength in diversity: Understanding the pathways to herpes simplex
433 virus reactivation. *Virology* 522:81-91.
- 434 11. Cliffe AR, Garber DA, Knipe DM. 2009. Transcription of the herpes simplex virus latency-
435 associated transcript promotes the formation of facultative heterochromatin on lytic
436 promoters. *J Virol* 83:8182-90.
- 437 12. Knipe DM, Cliffe A. 2008. Chromatin control of herpes simplex virus lytic and latent infection.
438 *Nat Rev Microbiol* 6:211-21.
- 439 13. Wang QY, Zhou C, Johnson KE, Colgrove RC, Coen DM, Knipe DM. 2005. Herpesviral latency-
440 associated transcript gene promotes assembly of heterochromatin on viral lytic-gene
441 promoters in latent infection. *Proc Natl Acad Sci U S A* 102:16055-9.
- 442 14. Kwiatkowski DL, Thompson HW, Bloom DC. 2009. The polycomb group protein Bmi1 binds to
443 the herpes simplex virus 1 latent genome and maintains repressive histone marks during
444 latency. *J Virol* 83:8173-81.
- 445 15. Nicoll MP, Hann W, Shivkumar M, Harman LE, Connor V, Coleman HM, Proenca JT, Efstathiou
446 S. 2016. The HSV-1 Latency-Associated Transcript Functions to Repress Latent Phase Lytic
447 Gene Expression and Suppress Virus Reactivation from Latently Infected Neurons. *PLoS*
448 *Pathog* 12:e1005539.
- 449 16. Liang Y, Vogel JL, Narayanan A, Peng H, Kristie TM. 2009. Inhibition of the histone
450 demethylase LSD1 blocks alpha-herpesvirus lytic replication and reactivation from latency. *Nat*
451 *Med* 15:1312-7.

- 452 17. Dochnal SA, Francois AK, Cliffe AR. 2021. De Novo Polycomb Recruitment: Lessons from Latent
453 Herpesviruses. *Viruses* 13.
- 454 18. Umbach JL, Kramer MF, Jurak I, Karnowski HW, Coen DM, Cullen BR. 2008. MicroRNAs
455 expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs. *Nature*
456 454:780-3.
- 457 19. Jurak I, Kramer MF, Mellor JC, van Lint AL, Roth FP, Knipe DM, Coen DM. 2010. Numerous
458 conserved and divergent microRNAs expressed by herpes simplex viruses 1 and 2. *J Virol*
459 84:4659-72.
- 460 20. Kramer MF, Jurak I, Pesola JM, Boissel S, Knipe DM, Coen DM. 2011. Herpes simplex virus 1
461 microRNAs expressed abundantly during latent infection are not essential for latency in
462 mouse trigeminal ganglia. *Virology* 417:239-47.
- 463 21. Jurak I, Hackenberg M, Kim JY, Pesola JM, Everett RD, Preston CM, Wilson AC, Coen DM. 2014.
464 Expression of herpes simplex virus 1 microRNAs in cell culture models of quiescent and latent
465 infection. *J Virol* 88:2337-9.
- 466 22. Pan D, Flores O, Umbach JL, Pesola JM, Bentley P, Rosato PC, Leib DA, Cullen BR, Coen DM.
467 2014. A neuron-specific host microRNA targets herpes simplex virus-1 ICP0 expression and
468 promotes latency. *Cell Host Microbe* 15:446-56.
- 469 23. Roizman B, Knipe DM, Whitley R. 2013. Herpes simplex viruses, 6th ed. Lippincott Williams
470 & Wilkins, Philadelphia.
- 471 24. Dremel SE, DeLuca NA. 2019. Genome replication affects transcription factor binding
472 mediating the cascade of herpes simplex virus transcription. *Proc Natl Acad Sci U S A*
473 116:3734-3739.
- 474 25. Kim JY, Mandarino A, Chao MV, Mohr I, Wilson AC. 2012. Transient reversal of episome
475 silencing precedes VP16-dependent transcription during reactivation of latent HSV-1 in
476 neurons. *PLoS Pathog* 8:e1002540.
- 477 26. Cliffe AR, Wilson AC. 2017. Restarting Lytic Gene Transcription at the Onset of Herpes Simplex
478 Virus Reactivation. *J Virol* 91:e01419-16-6.
- 479 27. Cliffe AR, Arbuckle JH, Vogel JL, Geden MJ, Rothbart SB, Cusack CL, Strahl BD, Kristie TM,
480 Deshmukh M. 2015. Neuronal Stress Pathway Mediating a Histone Methyl/Phospho Switch Is
481 Required for Herpes Simplex Virus Reactivation. *Cell Host Microbe* 18:649-58.
- 482 28. Wilcox CL, Johnson EM, Jr. 1987. Nerve growth factor deprivation results in the reactivation of
483 latent herpes simplex virus in vitro. *J Virol* 61:2311-5.
- 484 29. Yanez AA, Harrell T, Sriranganathan HJ, Ives AM, Bertke AS. 2017. Neurotrophic Factors NGF,
485 GDNF and NTN Selectively Modulate HSV1 and HSV2 Lytic Infection and Reactivation in
486 Primary Adult Sensory and Autonomic Neurons. *Pathogens* 6:5-13.
- 487 30. Cuddy SR, Schinlever AR, Dochnal S, Seegren PV, Suzich J, Kundu P, Downs TK, Farah M, Desai
488 BN, Boutell C, Cliffe AR. 2020. Neuronal hyperexcitability is a DLK-dependent trigger of herpes
489 simplex virus reactivation that can be induced by IL-1. *Elife* 9.
- 490 31. Hu HL, Shiflett LA, Kobayashi M, Chao MV, Wilson AC, Mohr I, Huang TT. 2019. TOP2beta-
491 Dependent Nuclear DNA Damage Shapes Extracellular Growth Factor Responses via Dynamic
492 AKT Phosphorylation to Control Virus Latency. *Mol Cell* 74:466-480 e4.
- 493 32. Tedeschi A, Bradke F. 2013. The DLK signalling pathway--a double-edged sword in neural
494 development and regeneration. *EMBO Rep* 14:605-14.
- 495 33. Sengupta Ghosh A, Wang B, Pozniak CD, Chen M, Watts RJ, Lewcock JW. 2011. DLK induces
496 developmental neuronal degeneration via selective regulation of proapoptotic JNK activity.
497 *The Journal of Cell Biology* 194:751-764.

- 498 34. Kurapati S, Sadaoka T, Rajbhandari L, Jagdish B, Shukla P, Ali MA, Kim YJ, Lee G, Cohen JL,
499 Venkatesan A. 2017. Role of the JNK Pathway in Varicella-Zoster Virus Lytic Infection and
500 Reactivation. *J Virol* 91.
- 501 35. Camarena V, Kobayashi M, Kim JY, Roehm P, Perez R, Gardner J, Wilson AC, Mohr I, Chao MV.
502 2010. Nature and duration of growth factor signaling through receptor tyrosine kinases
503 regulates HSV-1 latency in neurons. *Cell Host Microbe* 8:320-30.
- 504 36. Suzich JB, Cuddy SR, Baidas H, Dochnal S, Ke E, Schinlever AR, Babnis A, Boutell C, Cliffe AR.
505 2021. PML-NB-dependent type I interferon memory results in a restricted form of HSV
506 latency. *EMBO Rep* 22:e52547.
- 507 37. Hu HL, Srinivas KP, Wang S, Chao MV, Lionnet T, Mohr I, Wilson AC, Depledge DP, Huang TT.
508 2022. Single-cell transcriptomics identifies Gadd45b as a regulator of herpesvirus-reactivating
509 neurons. *EMBO Rep* 23:e53543.
- 510 38. Liang Y, Vogel JL, Arbuckle JH, Rai G, Jadhav A, Simeonov A, Maloney DJ, Kristie TM. 2013.
511 Targeting the JMJD2 histone demethylases to epigenetically control herpesvirus infection and
512 reactivation from latency. *Sci Transl Med* 5:167ra5.
- 513 39. Baringer JR, Swoveland P. 1973. Recovery of herpes-simplex virus from human trigeminal
514 ganglions. *N Engl J Med* 288:648-50.
- 515 40. Richter ER, Dias JK, Gilbert JE, 2nd, Atherton SS. 2009. Distribution of herpes simplex virus
516 type 1 and varicella zoster virus in ganglia of the human head and neck. *J Infect Dis* 200:1901-
517 6.
- 518 41. Warren KG, Brown SM, Wroblewska Z, Gilden D, Koprowski H, Subak-Sharpe J. 1978. Isolation
519 of latent herpes simplex virus from the superior cervical and vagus ganglions of human beings.
520 *N Engl J Med* 298:1068-9.
- 521 42. Riccio RE, Park SJ, Longnecker R, Kopp SJ. 2019. Characterization of Sex Differences in Ocular
522 Herpes Simplex Virus 1 Infection and Herpes Stromal Keratitis Pathogenesis of Wild-Type and
523 Herpesvirus Entry Mediator Knockout Mice. *mSphere* 4.
- 524 43. Du T, Zhou G, Roizman B. 2011. HSV-1 gene expression from reactivated ganglia is disordered
525 and concurrent with suppression of latency-associated transcript and miRNAs. *Proc Natl Acad*
526 *Sci U S A* 108:18820-4.
- 527 44. Messer HG, Jacobs D, Dhummakupt A, Bloom DC. 2015. Inhibition of H3K27me3-specific
528 histone demethylases JMJD3 and UTX blocks reactivation of herpes simplex virus 1 in
529 trigeminal ganglion neurons. *J Virol* 89:3417-20.
- 530 45. Liang Y, Quenelle D, Vogel JL, Mascaro C, Ortega A, Kristie TM. 2013. A novel selective
531 LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and
532 reactivation from latency. *mBio* 4:e00558-12.
- 533 46. Fletcher GC, Xue L, Passingham SK, Tolkovsky AM. 2000. Death commitment point is advanced
534 by axotomy in sympathetic neurons. *J Cell Biol* 150:741-54.
- 535 47. Wu CC, Wu HJ, Wang CH, Lin CH, Hsu SC, Chen YR, Hsiao M, Schuyler SC, Lu FL, Ma N, Lu J.
536 2015. Akt suppresses DLK for maintaining self-renewal of mouse embryonic stem cells. *Cell*
537 *Cycle* 14:1207-17.
- 538 48. Asghari Adib E, Smithson LJ, Collins CA. 2018. An axonal stress response pathway:
539 degenerative and regenerative signaling by DLK. *Curr Opin Neurobiol* 53:110-119.
- 540 49. Huntwork-Rodriguez S, Wang B, Watkins T, Ghosh AS, Pozniak CD, Bustos D, Newton K,
541 Kirkpatrick DS, Lewcock JW. 2013. JNK-mediated phosphorylation of DLK suppresses its
542 ubiquitination to promote neuronal apoptosis. *J Cell Biol* 202:747-63.

- 543 50. Watkins TA, Wang B, Huntwork-Rodriguez S, Yang J, Jiang Z, Eastham-Anderson J, Modrusan Z,
544 Kaminker JS, Tessier-Lavigne M, Lewcock JW. 2013. DLK initiates a transcriptional program
545 that couples apoptotic and regenerative responses to axonal injury. *Proc Natl Acad Sci U S A*
546 110:4039-44.
- 547 51. Kole AJ, Annis RP, Deshmukh M. 2013. Mature neurons: equipped for survival. *Cell Death Dis*
548 4:e689.
- 549 52. Fischle W, Wang Y, Allis CD. 2003. Binary switches and modification cassettes in histone
550 biology and beyond. *Nature* 425:475-9.
- 551 53. Fischle W, Tseng BS, Dormann HL, Ueberheide BM, Garcia BA, Shabanowitz J, Hunt DF,
552 Funabiki H, Allis CD. 2005. Regulation of HP1-chromatin binding by histone H3 methylation
553 and phosphorylation. *Nature* 438:1116-22.
- 554